Keytruda taught Merck how to build a blockbuster. But
manufacturing a 2nd lightning bolt is easier said than done
Merck's Keytruda has dazzled since first nabbing approval in 2014, earning billions of dollars in revenue and expanding its reach to more than a dozen cancers. But as the drug's patent expiration nears, can Merck manufacture a second clinical lightning strike?
No comments:
Post a Comment